The CPDMU is a Shared Resource used by all AECC clinical cancer researchers that provides centralized management, communication, and oversight of all cancer clinical trials at the AECC. The CPDMU provides a central location for processing of all cancer related protocols, interaction with internal (e.g., IRB) and external (e.g., NCI, industry) agencies, and communication. The scope of work performed by the CPDMU includes processing of initial protocol submissions, amendments, internal and external safety and/or adverse event reports, and annual IRB progress reports, as well as patient registration, radiology review/tumor measurement, Data and Safety Monitoring Committee (DSMC reports, data management, and quality assurance). The CPDMU also supports other components of the clinical trials infrastructure, including the Protocol Review and Monitoring System (PRMS) and Protocol Specific Research Support (PSRS). Upon protocol activation, an announcement is distributed to all AECC investigators, and an updated list of currently active protocols is distributed on a monthly basis. The protocol status (open, suspended, closed to accrual) and most recently approved version of the protocol and IRB-approved consent is also posted on the CPDMU website so that it is accessible to all health care providers and research associates. Quality control functions include centralized education and training services for physicians, research nurses, physician assistants, and study coordinators. During the July 1, 2011 to June 30, 201212 grant year, the CPDMU processed 124 new protocols and 525 protocol amendments for review by the Protocol Review and Monitoring Committee (PRMC) and IRB, 5136 adverse events and 26 protocol monitoring reports for the DSMC, and 670 patient registrations requiring data management and processing.

Public Health Relevance

The Central Protocol and Data Management Unit (CPDMU) provides centralized management communication, and oversight for all cancer related clinical trials at the Albert Einstein Cancer Center (AECC). As an NCI-designated Cancer Center, AECC contributes to the national effort to reduce morbidity and mortality from cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA013330-41
Application #
8753319
Study Section
Subcommittee B - Comprehensiveness (NCI)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
41
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Albert Einstein College of Medicine
Department
Type
DUNS #
City
Bronx
State
NY
Country
United States
Zip Code
10461
Mao, Serena P H; Park, Minji; Cabrera, Ramon M et al. (2018) Loss of amphiregulin reduces myoepithelial cell coverage of mammary ducts and alters breast tumor growth. Breast Cancer Res 20:131
Mocholi, Enric; Dowling, Samuel D; Botbol, Yair et al. (2018) Autophagy Is a Tolerance-Avoidance Mechanism that Modulates TCR-Mediated Signaling and Cell Metabolism to Prevent Induction of T Cell Anergy. Cell Rep 24:1136-1150
Yang, Chia-Ping Huang; Wang, Changwei; Ojima, Iwao et al. (2018) Taxol Analogues Exhibit Differential Effects on Photoaffinity Labeling of ?-Tubulin and the Multidrug Resistance Associated P-Glycoprotein. J Nat Prod 81:600-606
Guan, Fangxia; Tabrizian, Tahmineh; Novaj, Ardijana et al. (2018) Dietary Walnuts Protect Against Obesity-Driven Intestinal Stem Cell Decline and Tumorigenesis. Front Nutr 5:37
Wang, Tao; Hosgood, H Dean; Lan, Qing et al. (2018) The Relationship Between Population Attributable Fraction and Heritability in Genetic Studies. Front Genet 9:352
Chennamadhavuni, Divya; Saavedra-Avila, Noemi Alejandra; Carreño, Leandro J et al. (2018) Dual Modifications of ?-Galactosylceramide Synergize to Promote Activation of Human Invariant Natural Killer T Cells and Stimulate Anti-tumor Immunity. Cell Chem Biol 25:571-584.e8
Limi, Saima; Senecal, Adrien; Coleman, Robert et al. (2018) Transcriptional burst fraction and size dynamics during lens fiber cell differentiation and detailed insights into the denucleation process. J Biol Chem 293:13176-13190
Rocha, Agostinho G; Franco, Antonietta; Krezel, Andrzej M et al. (2018) MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2A. Science 360:336-341
Cabahug-Zuckerman, Pamela; Stout Jr, Randy F; Majeska, Robert J et al. (2018) Potential role for a specialized ?3 integrin-based structure on osteocyte processes in bone mechanosensation. J Orthop Res 36:642-652
Vilchèze, Catherine; Copeland, Jacqueline; Keiser, Tracy L et al. (2018) Rational Design of Biosafety Level 2-Approved, Multidrug-Resistant Strains of Mycobacterium tuberculosis through Nutrient Auxotrophy. MBio 9:

Showing the most recent 10 out of 1508 publications